Font size
- 1 2 3 + Font size

click to adjust

Page tools
Search
. Advanced search






 

 

 

 

 

 

 

 

 

 



A Targeted Approach to HealthCare

Bayer HealthCare Pharmaceuticals' goal is to discover products that will improve human health worldwide by diagnosing, preventing and treating diseases. As a specialty pharmaceutical company, we focus our efforts where we can have the most impact.

For more than 100 years, Bayer has been dedicated to developing, manufacturing and marketing pharmaceuticals. Built on the company's long history of providing medicines that healthcare providers and patients can trust, Bayer is one of the most recognized brands in health care.


Bayer News Releases


28 June 2010 - Bayer News Releases....... Bayer HealthCare Introduces First Mobile Application to Assist Hemophilia A Patients in Managing their Treatment more

17 June 2010 - Bayer News Releases....... Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures more

15 June 2010 - Bayer News Releases....... Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Teva’s Generic Oral Contraceptive GianviTM more

14 June 2010 - Bayer News Releases....... Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival more

17 May 2010 - Bayer News Releases....... Bayer HealthCare Enhances U.S. Research Strategy with New Innovation Center more

6 May 2010 - Bayer News Releases....... U.S. FDA APPROVES NATAZIATM, A NEW ORAL CONTRACEPTIVE FOR THE PREVENTION OF PREGNANCY more

17 April 2010 - Bayer News Releases....... Bayer HealthCare Marks 2010 World Hemophilia Day with a $350,000 Contribution to the World Federation of Hemophilia more

9 April 2010 - Bayer News Releases....... BAYER UPDATES LABELS FOR YAZ and YASMIN Body of Evidence Affirms VTE Risk/Benefit Profile for YAZ and Yasmin Is Comparable to Other Combination Oral Contraceptives more

11 March 2010 - Bayer News Releases....... FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis more

 

Press Release Archive

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Further Information


Important Avelox® Safety Information for US Healthcare Professionals and Patients

Medication Guide for Patients

Updated Avelox Prescribing Information

Dear Healthcare Professional Letter

Important Trasylol® Safety Information

New - Important Information for Health Professionals

Clinical Trials

Information about clinical studies is available in the Bayer HealthCare database  as well as at clinicaltrials.gov
and  clinicalstudyresults.org.

Bayer Reports Findings of Trasylol Independent Investigation

Press Statement
Investigator Report
Key Committees - Bayer Global Drug Safety

http://pharma.bayer.com/scripts/pages/en/index.php

Copyright © Bayer Healthcare Pharmaceuticals